2-(2-甲氧基乙基)-6-甲基吡啶 | 71172-56-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(2-甲氧基乙基)-6-甲基吡啶
• 英文名称: 2-(2-methoxyethyl)-6-methylpyridine
• CAS: 71172-56-0
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: ZKQBRFRQZNYNQI-UHFFFAOYSA-N

物化性质

• 保留指数：
  1144.2

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  苯硼酸酐 、 2-(2-甲氧基乙基)-6-甲基吡啶 在 亚磷酸三苯酯 、 甲醇 、 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以38%的产率得到2-methyl-6-phenethylpyridine
  参考文献：
  名称：

  Ruthenium-Catalyzed Conversion of sp³ C–O Bonds in Ethers to C–C Bonds Using Triarylboroxines

  摘要：

  Catalytic conversion of unreactive sp(3) C-O bonds in alkyl ethers to C-C bonds is described. Alkyl ethers bearing 2- or 4-pyridyl groups were coupled with triarylboroxines in the presence of a ruthenium catalyst. Triarylboroxines bearing a variety of functional groups including electron-withdrawing and -donating groups can be used for the reaction. No additional base was required for the coupling with the organoboron reagents, and base-sensitive groups can be tolerated. The reaction is considered to proceed via dehydroalkoxylation followed by addition of triarylboroxines to form C-C bonds.

  DOI：

  10.1021/ol2012007
• 作为产物：
  描述：

  2,6-二甲基吡啶 、 氯甲基甲基醚 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.0h， 以20%的产率得到2-(2-甲氧基乙基)-6-甲基吡啶
  参考文献：
  名称：

  Ruthenium-Catalyzed Conversion of sp³ C–O Bonds in Ethers to C–C Bonds Using Triarylboroxines

  摘要：

  Catalytic conversion of unreactive sp(3) C-O bonds in alkyl ethers to C-C bonds is described. Alkyl ethers bearing 2- or 4-pyridyl groups were coupled with triarylboroxines in the presence of a ruthenium catalyst. Triarylboroxines bearing a variety of functional groups including electron-withdrawing and -donating groups can be used for the reaction. No additional base was required for the coupling with the organoboron reagents, and base-sensitive groups can be tolerated. The reaction is considered to proceed via dehydroalkoxylation followed by addition of triarylboroxines to form C-C bonds.

  DOI：

  10.1021/ol2012007

文献信息

• [EN] BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS<br/>[FR] UTILISATION DE LACTAMES DE TRIAZOLE ET DE PYRAZOLE BICYCLIQUES COMME MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MGLUR5
  申请人：UNIV VANDERBILT

  公开号：WO2012083224A1

  公开（公告）日：2012-06-21

  In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及到双环三唑和吡唑内酰胺，它们的衍生物以及相关化合物，这些化合物可用作代谢型谷氨酸受体亚型5（mGluR5）的正向变构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意味着对本发明的限制。
• BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
  申请人：Conn P. Jeffrey

  公开号：US20120225844A1

  公开（公告）日：2012-09-06

  In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及双环三唑和吡唑内酰胺、其衍生物和相关化合物，可作为代谢型谷氨酸受体亚型5（mGluR5）的正向变构调节剂；制备这些化合物的合成方法；包含这些化合物的制药组合物；以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神障碍的方法。本摘要旨在作为特定领域搜索的扫描工具，不限制本发明。
• NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2900223B1

  公开（公告）日：2017-10-25
• US7291644B2
  申请人：——

  公开号：US7291644B2

  公开（公告）日：2007-11-06
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：NUVATION BIO INC

  公开号：WO2020150675A1

  公开（公告）日：2020-07-23

  Compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.